Drug · CHEMBL1703
METFORMIN HYDROCHLORIDE
7 sourcespipelines-2026-09-18-0.3.1
Download JSON
Cite this record
ConductScience Library. METFORMIN HYDROCHLORIDE. Drugs and targets, record CHEMBL1703. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL1703
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Brand names
Bolamyn sr, Diagemet xl, Fortamet, Glucamet 500, Glucamet 850, Glucient sr, Glucophage, Glucophage sr, Glucophage xr, Glumetza, Glyformin, Ledermetin, Metabet sr, Metformin hydrochloride component of actoplus met, Metformin hydrochloride component of avandamet, Metformin hydrochloride component of glucovance, Metformin hydrochloride component of invokamet, Metformin hydrochloride component of janumet, Metformin hydrochloride component of jentadueto, Metformin hydrochloride component of kazano, Metformin hydrochloride component of kombiglyze xr, Metformin hydrochloride component of metaglip, Metformin hydrochloride component of prandimet, Metformin hydrochloride component of qternmet, Metformin hydrochloride component of qternmet xr, Metformin hydrochloride component of segluromet, Metformin hydrochloride component of synjardy, Metformin hydrochloride component of trijardy xr, Metformin hydrochloride component of xigduo, Metformin hydrochloride component of zituvimet, Metsol, Milform, Orabet, Riomet, Riomet er, Sukkarto sr
- ChEMBL
- Other names
- Apophage, Benofomin, Diabefagos, Diabex, EX-404, EX404, Glucaminol, LA-6023, Metformin hcl, NSC-91485, Neodipa, Siamformet, Walaphage
- ChEMBL
- Open Targets' highest stage
- Approval, for 2 of its 41 diseases, from DailyMed, EMA Human Drugs, FDA and PMDA
- Open Targets
Targets51
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| COXFA4 | Mitochondrial complex I (NADH dehydrogenase) | Mitochondrial complex I (NADH dehydrogenase) inhibitor | INHIBITOR | https://conductscience.org/library/genes/4697 |
| COXFA4L2 | Mitochondrial complex I (NADH dehydrogenase) | Mitochondrial complex I (NADH dehydrogenase) inhibitor | INHIBITOR | https://conductscience.org/library/genes/56901 |
| GPD2 | Glycerol-3-phosphate dehydrogenase, mitochondrial | Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor | INHIBITOR | https://conductscience.org/library/genes/2820 |
| MT-ND1 | Mitochondrial complex I (NADH dehydrogenase) | Mitochondrial complex I (NADH dehydrogenase) inhibitor | INHIBITOR | https://conductscience.org/library/genes/4535 |
| MT-ND2 | Mitochondrial complex I (NADH dehydrogenase) | Mitochondrial complex I (NADH dehydrogenase) inhibitor | INHIBITOR | https://conductscience.org/library/genes/4536 |
| MT-ND3 | Mitochondrial complex I (NADH dehydrogenase) | Mitochondrial complex I (NADH dehydrogenase) inhibitor | INHIBITOR | https://conductscience.org/library/genes/4537 |
| MT-ND4 | Mitochondrial complex I (NADH dehydrogenase) | Mitochondrial complex I (NADH dehydrogenase) inhibitor | INHIBITOR | https://conductscience.org/library/genes/4538 |
| MT-ND4L | Mitochondrial complex I (NADH dehydrogenase) | Mitochondrial complex I (NADH dehydrogenase) inhibitor | INHIBITOR | https://conductscience.org/library/genes/4539 |
| MT-ND5 | Mitochondrial complex I (NADH dehydrogenase) | Mitochondrial complex I (NADH dehydrogenase) inhibitor | INHIBITOR | https://conductscience.org/library/genes/4540 |
| MT-ND6 | Mitochondrial complex I (NADH dehydrogenase) | Mitochondrial complex I (NADH dehydrogenase) inhibitor | INHIBITOR | https://conductscience.org/library/genes/4541 |
1 to 10 of 51Source ChEMBL
See all 51 targetsDiseases41
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| type 2 diabetes mellitus | Approval | DailyMed, EMA Human Drugs, FDA and PMDA | 172 | 27 | https://conductscience.org/library/drugs?q=MONDO_0005148 |
| prostate cancer | Phase 2 | ClinicalTrials.gov | 5 | 5 | https://conductscience.org/library/drugs?q=MONDO_0008315 |
| breast cancer | Phase 2 | ClinicalTrials.gov | 4 | 4 | https://conductscience.org/library/drugs?q=MONDO_0007254 |
| polycystic ovary syndrome | Phase 2/3 | ClinicalTrials.gov and TTD | 4 | 3 | https://conductscience.org/library/drugs?q=MONDO_0008487 |
| Insulin resistance | Phase 3 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=HP_0000855 |
| endometrial cancer | Phase 2/3 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0011962 |
| malignant pancreatic neoplasm | Phase 2 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0009831 |
| pancreatic neoplasm | Phase 2 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0021040 |
| fallopian tube cancer | Phase 2 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0002158 |
| obesity disorder | Phase 3 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0011122 |
1 to 10 of 41Source Open Targets
See all 41 diseasesTrials137
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 3 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00482729 | MK0431A Comparative Study in Patients With Type 2 Diabetes (0431A-079)(COMPLETED) | Phase 3 | 1,246 | 2010-03-15 | metformin hydrochloride | Its name | ClinicalTrials.gov |
| NCT02980276 | RCT Metformin for Reduction of Gestational Diabetes Mellitus Effects | Phase 3 | 535 | 2025-03-17 | metformin hydrochloride | Its name | ClinicalTrials.gov |
| NCT02065687 | Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer | Phase 2/3 | 469 | 2021-01-12 | metformin hydrochloride | Its name | ClinicalTrials.gov |
| NCT00131664 | Avandia™ + Amaryl™ or Avandamet™ Compared With Metformin (AVALANCHE™ Study) | Phase 3 | 391 | 2013-04-17 | metformin hydrochloride | Its name | ClinicalTrials.gov |
| NCT02068443 | Comparative Study to Evaluate Efficacy and Safety When Metformin Hydrochloride 500 mg Once Daily is Added on to SYR-322 25 mg in Type 2 Diabetic Patients With Inadequate Glycemic Control Despite Treatment With SYR-322 25 mg in Addition to Diet and Exercise Therapy | Phase 3 | 374 | 2016-06-06 | metformin hydrochloride | Its name | ClinicalTrials.gov |
| NCT04288778 | A Study to Assess Safety of Canagliflozin and Metformin Hydrochloride Combination Given as a Supplement to Diet and Exercise to Improve Blood Sugar Level in Indian Adult Participants With Diabetes | Phase 4 | 276 | 2023-08-18 | metformin hydrochloride | Its name | ClinicalTrials.gov |
| NCT02186847 | Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer | Phase 2 | 170 | 2020-06-23 | metformin hydrochloride | Its name | ClinicalTrials.gov |
| NCT01447927 | Metformin Hydrochloride in Preventing Esophageal Cancer in Patients With Barrett Esophagus | Phase 2 | 93 | 2014-07-21 | metformin hydrochloride | Its name | ClinicalTrials.gov |
| NCT01905046 | Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer | Phase 3 | 86 | 2025-04-13 | metformin hydrochloride | Its name | ClinicalTrials.gov |
| NCT00929201 | Sitagliptin/Metformin Fed Bioequivalence Study (0431A-080) | Phase 1 | 61 | 2010-02-01 | metformin hydrochloride, sitagliptin phosphate/metformin hydrochloride | Its name | ClinicalTrials.gov |
1 to 10 of 137
See all 137 trialsComparisons in its trials51
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Sita/Met FDC vs Metformin: serious adverse events | 28 of 625 | 38 of 621 | 1,246 | NCT00482729 | Trial comparisons |
| Treatment vs Control: Insulation of Insulin | 101 of 264 | 134 of 262 | 526 | NCT02980276 | Trial comparisons |
| Treatment vs Control: Primary Composite Outcome | 150 of 264 | 167 of 262 | 526 | NCT02980276 | Trial comparisons |
| Treatment vs Control: Insulin Initiated | 94 of 263 | 106 of 262 | 525 | NCT02980276 | Trial comparisons |
| Treatment vs Control: Neonatal Morbidity - Neonatal Hypoglycemia | 36 of 262 | 34 of 262 | 524 | NCT02980276 | Trial comparisons |
| Treatment vs Control: Neonatal Morbidity - Apgar Score <7 at 5 Minutes | 1 of 262 | 1 of 262 | 524 | NCT02980276 | Trial comparisons |
| Treatment vs Control: Maternal Morbidity - Antepartum Hemorrhage | 15 of 262 | 27 of 262 | 524 | NCT02980276 | Trial comparisons |
| Treatment vs Control: Neonatal Morbidity - Major Congenital Anomalies | 10 of 262 | 7 of 262 | 524 | NCT02980276 | Trial comparisons |
| Treatment vs Control: Maternal Morbidity - Postpartum Hemorrhage | 51 of 262 | 63 of 262 | 524 | NCT02980276 | Trial comparisons |
| Treatment vs Control: Neonatal Morbidity - Jaundice Requiring Phototherapy | 1 of 262 | 0 of 262 | 524 | NCT02980276 | Trial comparisons |
1 to 10 of 51
See all 51 comparisons in its trialsPapers from its trials34
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL1703
GET https://conductscience.org/api/drugs/v1/CHEMBL1703/targets?page=2